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Abstract
Background: Tumor angiogenesis is a highly regulated process involving intercellular communication as well as the
interactions of multiple downstream signal transduction pathways. Disrupting one or even a few angiogenesis pathways
is often insufficient to achieve sustained therapeutic benefits due to the complexity of angiogenesis. Targeting multiple
angiogenic pathways has been increasingly recognized as a viable strategy. However, translation of the polypharmacology
of a given compound to its antiangiogenic efficacy remains a major technical challenge. Developing a global functional
association network among angiogenesis-related genes is much needed to facilitate holistic understanding of angiogenesis
and to aid the development of more effective anti-angiogenesis therapeutics.
Results: We constructed a comprehensive gene functional association network or interactome by transcript profiling
an in vitro angiogenesis model, in which human umbilical vein endothelial cells (HUVECs) formed capillary structures
when co-cultured with normal human dermal fibroblasts (NHDFs). HUVEC competence and NHDF supportiveness of
cord formation were found to be highly cell-passage dependent. An enrichment test of Biological Processes (BP) of
differentially expressed genes (DEG) revealed that angiogenesis related BP categories significantly changed with cell
passages. Built upon 2012 DEGs identified from two microarray studies, the resulting interactome captured 17226
functional gene associations and displayed characteristics of a scale-free network. The interactome includes the
involvement of oncogenes and tumor suppressor genes in angiogenesis. We developed a network walking algorithm to
extract connectivity information from the interactome and applied it to simulate the level of network perturbation by
three multi-targeted anti-angiogenic kinase inhibitors. Simulated network perturbation correlated with observed anti-
angiogenesis activity in a cord formation bioassay.
Conclusion: We established a comprehensive gene functional association network to model in vitro angiogenesis
regulation. The present study provided a proof-of-concept pilot of applying network perturbation analysis to drug
phenotypic activity assessment.
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Background
Angiogenesis, the generation of new blood vessels, plays
an essential role under normal physiological conditions
as well as during the pathogenesis of many diseases
including atherosclerosis, macular degeneration, wound
healing, diabetic retinopathy, and human malignancy [1-
3]. Remarkably, tumor dormancy is believed to be attrib-
uted, at least in part, to the lack of angiogenesis support.
The transition from an avascular, dormant tumor to an
aggressively growing angiogenic cancer is referred to as the
"angiogenic switch" [4,5]. More than 30 years ago, it was
hypothesized that inhibition of tumor angiogenesis
would inhibit solid tumor growth [6]. Since then, the
expansion of angiogenesis research has resulted in the
identification of various pro- and anti-angiogenic factors,
such as FGF, VEGF, angiopoietin, endostatin, vasostatin,
and neuronal cell axon guidance molecules [2,7-9] and
the development of several anti-tumor angiogenesis med-
icines that have recently proven efficacious in the clinic
[1,2,7,10,11].
Malignant tumors often express an array of angiogenic
factors to potentiate angiogenesis and tumor growth [8].
Ultimate angiogenic outcomes depend on the dynamic
equilibrium between positive and negative regulators and
the interplay among their signal transduction pathways,
not on a single discrete pathway. Avastin, a monoclonal
antibody that specifically blocks VEGF, is the first
approved anti-angiogenic therapy. Notably, combination
with chemotherapies has been necessary for its clinical
efficacy. Moreover, tumors often develop drug resistance
in response to anti-VEGF therapy [12]. Hanahan et al
demonstrated one possible mechanism by which such
drug resistance might develop[13]. Inhibition of VEGF
signalling by neutralizing antibody to VEGFR2 (KDR)
induces elevated expression of hypoxia associated proan-
giogenic factors such as FGF and EphrinA1, which subse-
quently reactivates VEGF independent angiogenesis and
tumor growth. Thus, disrupting a single proangiogenic
pathway by itself is often insufficient to achieve sustained
therapeutic benefits. In this light, it is necessary to explore
global functional association among angiogenesis-related
genes rather than focusing on an individual or a few ang-
iogenesis factors discretely.
Importantly, angiogenesis involves intercellular interac-
tion among vessel-forming endothelial cells, nonmalig-
nant cells such as the supporting pericytes, immune and
stromal cells, as well as the malignant tumor cells [1,14].
Therefore, global gene-gene interactions during angiogen-
esis need to be explored in a multi-cell type context.
Human umbilical vein endothelial cells (HUVECs) are
widely used to study vascular biology [15]. They form a
lumen bearing capillary structure when co-cultured with
normal human dermal fibroblast (NHDF) cells [16]. It
has also been noticed that HUVECs change their cellular
and molecular properties upon passage in vitro, a phe-
nomenon thought to be due to in vitro cellular senescence
[17-20]. In the present study, we determined that HUVEC
competence and NHDF supportiveness for angiogenesis
in this co-culture system are both cell passage dependent.
Gene Ontology (GO) analysis of differentially expressed
genes showed that the cell passage dependent global tran-
scriptional changes are highly related to angiogenesis.
This enabled us to construct a comprehensive functional
association network of differentially expressed genes
using a natural language processing algorithm. We further
developed a "network walking" algorithm to estimate net-
work perturbation by small molecule kinase inhibitors.
The simulated compound activity via network perturba-
tion analysis was in good agreement with actual pheno-
typic activity in the cord formation bioassay.
Results
Characterization of an in vitro angiogenesis co-culture 
model by multi parameter high content image analysis
HUVECs form a capillary structure when co-cultured with
NHDF in vitro [16]. Unlike the HUVEC Matrigel™ assay,
the HUVEC/NHDF cord formation co-culture allows us to
study cell-cell interactions during long term (up to 14
days) angiogenesis. The formation of the cord structure is
a highly organized morphogenic process. We developed a
high content imaging based assay to document and quan-
titate cord formation using the Cellomics ArrayScan plat-
form. We were able to simultaneously assess dozens of
morphological measurements, such as tube length, area,
connectivity of the cord, branching, and number of nuclei
within the cord. Using this assay system, we tested a clin-
ically approved antiangiogenic compound Sunitinib
(SUTENT, SU11248). While 20 ng/ml VEGF significantly
increased angiogenesis, 30 nM Sunitinib significantly
inhibited angiogenesis (Fig. 1A).
To explore the phenotypic signatures induced by VEGF or
Sunitinib, we performed principal component analysis
(PCA) and hierarchical clustering (Fig. 1B &1C). Multivar-
iate analyses using 47 morphological measurements
clearly distinguished the three treatment groups, i.e. con-
trol, VEGF, and Sunitinib. In the PCA analysis, the first
three principal components captured more than 80% of
the total variance. Examining the PC loadings, we found
that among the most discriminative features are the cord
length (either connected or unconnected or in general),
cord area, the branching segment count. The cord CD31
immunofluorescence intensity is also one of the features
that significantly contributed to PC1, likely due to the
overall correlation of fluorescence staining to cord mass.
Interestingly, the cord width is not a discriminative fea-
ture for either VEGF or Sunitinib action. The current
multi-parameter, high content analysis allowed for aBMC Genomics 2008, 9:264 http://www.biomedcentral.com/1471-2164/9/264
Page 3 of 16
(page number not for citation purposes)
detailed dissection of the phenotypic characteristics asso-
ciated with a given factor or compound. Shown in Fig. 1D
is the mean value plot of a few representative parameters.
Sunitinib significantly inhibited the mass of the cord in
length and area, but not width. Moreover, the number of
nuclei per tube is significantly reduced, indicating that
Sunitinib could have anti-proliferation activity on
HUVECs in the co-culture. Sunitinib treated cultures are
less morphologically complex, as the number of con-
nected cords, the branching nodes, and segment measure-
ments are all significantly reduced.
Multi parameter characterization of in vitro angiogenesis in a co-culture model Figure 1
Multi parameter characterization of in vitro angiogenesis in a co-culture model. (A) HUVECs formed capillary 
structure (cord) when plated on dermal fibroblast cells over the period of 12–14 days. The angiogenic cord structure was vis-
ualized by human CD31 staining (green), fibroblast cells were stained with an intermediate filament marker vimentin (red), 
while the nucleus of both cell types were visualized with Hoechst staining (blue). Cord formation was greatly enhanced by addi-
tion of 20 ng/ml VEGF (VEGF) to the culture, while 30 nM Sunitinib (CMPD) drastically inhibited cord formation as compared 
to the medium control (CTL). (B). Morphological features of the cord formed in the co-culture were captured and quantitated 
by high content image analysis using the ArrayScan platform adopting the tube formation bioapplication. 47 measurements 
were assessed, normalized using the Z-score across different treatment groups and analyzed by Principal Component Analysis 
(PCA). The first three principal components accounting for more than 80% of the variance were selected for sample scatter 
plotting. Blue are the control cultures (CTL); yellow, cultures treated with 20 ng/ml VEGF; and red, cultures treated with 30 
nM Sunitinib (CMPD) treated samples. (C). The Z-scores of 47 morphological measurements were clustered in Spotfire Deci-
sion Site with the correlation coefficient being used as the distance metric. Complete linkage was used as the clustering algo-
rithm. Red stands for higher and green for lower than mean (black) expression. (D). Six representative parameters were 
selected and plotted. Except for the cord width, the cord length, area, branching point, the number of nucleus within the cord, 
and a composite angiogenesis index (Angio Index) all manifested the anti and pro angiogenic effects from Sunitinib and VEGF, 
respectively. Data are expressed as Mean ± S.D.BMC Genomics 2008, 9:264 http://www.biomedcentral.com/1471-2164/9/264
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HUVEC cord formation competence is cell passage 
dependent
It has been well known that HUVECs change their bio-
chemical and cellular behaviors when passaged in vitro
[17-20]. We cultured HUVEC cells from a single batch to
various passages (P6, P14, P22) and tested them for cord
formation competence. We found that they gradually lost
cord formation capabilities upon passage (Fig. 2A). While
early passage (P6) HUVECs formed very nice capillary
structures and responded robustly to VEGF when co-cul-
HUVEC passage dependent angiogenic competence in cord formation assay Figure 2
HUVEC passage dependent angiogenic competence in cord formation assay. HUVECs cultured to various passage 
numbers (P6, early; P14, intermediate; and P22, late) were co-cultured with NHDFs in the cord formation assay. The cord was 
visualized by human CD31 staining (green) and quantitated. The cultures were treated with or without 20 ng/ml exogenously 
added VEGF. Representative images are shown in (A). 6 well-level parameters were quantitated and plotted in (B). Please note 
that HUVECs gradually lost their cord formation competence when passaged in vitro. Data are expressed as Mean ± S.D. (C-
D). HUVECs with various passage numbers (P5, P8, P12, and P22) were assayed for basal gene expression using the Affymetrix 
GeneChip platform. A linear regression method was used to identify differentially expressed genes over cell passage. An 
enrichment testing was used to identify significantly changed Biological Process (BP) categories associated with HUVEC pas-
sage-dependent gene expression. Representative BP categories were shown using heatmap visualization, for genes associated 
with mitotic cell cycle (C), and cell death (D).BMC Genomics 2008, 9:264 http://www.biomedcentral.com/1471-2164/9/264
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tured with NHDF, late passage (P22) HUVECs lost cord
formation capability and had diminished response to
VEGF (Fig. 2A &2B).
We next profiled gene expression changes associated with
HUVEC passage. Since the loss of angiogenesis capability
was proportional to the round of cell passage, we applied
a statistical approach to identify genes with regressive
expression patterns, i.e. their expression either increased
or decreased over passage numbers. We identified 1103
differentially expressed (DE) genes which are listed in
Supplemental Table 1 (see Additional file 1). In order to
understand the biological relevance of the DE genes, we
analyzed the DE genes by using the DAVID functional
annotation system [21]. Table 1 lists Gene Ontology (GO)
terms significantly enriched with the DE genes. The most
significant Biological Processes (BP) categories are cell
cycle, proliferation and programmed cell death. Expres-
sion profiles of the DE genes involved in representative
biological processes were analyzed by hierarchical cluster-
ing analysis. The majority of the DE genes involved in
mitotic cell cycle and proliferation were down-regulated,
whereas the majority of genes related to cell death were
up-regulated (Fig. 2C–D), which supports the replicative
cell senescence hypothesis.
Profiling passage dependent angiogenesis support by 
dermal fibroblast cells
Long term sustained angiogenesis in co-culture is sup-
ported by dermal fibroblast feeder layer cells, which are
also affected by cell passage. While late passage (P12)
adult NHDFs demonstrated poor support for HUVECs to
form capillary structures, early passage (P5) adult cells did
well (Fig. 3A), suggesting that supportiveness of NHDFs
in the angiogenesis assay is indeed cell-passage depend-
ent. An early passage NHDF from a neonatal donor also
supported angiogenesis in this assay (Fig. 3A).
Differential angiogenesis supportiveness by NHDFs in the
co-culture system represents a unique opportunity for us
to dissect factors that may contribute to the complex inter-
cellular communications during angiogenesis. To assess
this, we profiled gene expression in the three listed prepa-
rations of NHDF cells by DNA microarray analysis.
Between the supportive NHDF cells versus the non-sup-
portive ones, we identified 787 non-redundant common
DE genes which are listed in Supplemental Table 2 (see
Additional file 2). Similarly, we used the DAVID func-
tional annotation system to examine the functional rele-
vance to angiogenesis of these DEGs. Table 2 lists the
significantly enriched GO terms. Interestingly, blood ves-
Table 1: Gene Ontology (GO) terms enriched with differentially expressed genes in HUVEC of different passages
GO1 GO Term DEG2 FDR3
Biological Process cell cycle 93 0.00075
mitotic cell cycle 44 0.00042
M phase of mitotic cell cycle 36 0.00124
programmed cell death 44 0.00717
mitosis 35 0.00511
cell division 37 0.00332
regulation of cell cycle 60 0.01370
cell cycle checkpoint 13 0.01512
cell organization and biogenesis 113 0.05000
cell proliferation 51 0.01164
Molecular Function protein binding 270 0.00051
ATP binding 106 0.00048
nucleotide binding 137 0.00473
catalytic activity 309 0.00144
purine nucleotide binding 119 0.00210
cytoskeletal protein binding 33 0.00545
kinase activity 70 0.03651
binding 545 0.03367
transferase activity 116 0.01551
Cellular Component spindle 14 0.00058
microtubule cytoskeleton 36 0.00182
intracellular 439 0.00138
cytoskeleton 73 0.00558
nucleus 237 0.00615
intracellular membrane-bound organelle 317 0.04183
intracellular organelle 364 0.01793
1. Gene Ontology; 2. Differentially expressed genes; 3. False discovery rate
Listed are GO categories identified through enrichment testing of the differentially expressed genes from HUVEC using the DAVID functional 
annotation system as described in the methods section.BMC Genomics 2008, 9:264 http://www.biomedcentral.com/1471-2164/9/264
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sel development and morphogenesis, angiogenesis and
vasculature development were among the most signifi-
cantly enriched biological processes, suggesting that these
molecular changes were related to cellular potential to
support angiogenesis. Representative expression profiles
of genes involved in blood vessel development and angio-
genesis are shown in Fig. 3B. This result is consistent with
the supporting roles of NHDFs in this co-culture system.
Taken together, passaging NHDF cells in vitro adversely
affects cellular capacity to support angiogenesis due to sig-
nificantly orchestrated changes of many genes involved in
a few related biological processes.
Establishment of a gene functional association network-
The fact that cell passage dependent gene expression in
both HUVEC and NHDF cells influences angiogenesis
supports modeling the angiogenesis network using the
DEGs identified by these DNA microarray experiments.
To understand the functional association of these genes,
we constructed a molecular interactome among the total
2012 differentially expressed genes identified from either
NHDFs or HUVECs. The interactome consisted of over
23,000 gene-to-gene connections retrieved from PubMed
abstracts using the natural language processing algorithm
in PathwayAssist. We then refined the interactome by
removing genes whose expression was not detectable by
microarray analysis in the co-culture system. The resulted
molecular interactome consists of 17226 molecular rela-
tionships described by the following terms: binding,
expression, molecular transport, protein modification
NHDF passage dependent angiogenic supportiveness in cord formation assay Figure 3
NHDF passage dependent angiogenic supportiveness in cord formation assay. P6 NHDFs from a neonatal donor, 
P5 and P12 NHDFs from an adult donor were tested for their angiogenesis supportiveness in the cord formation assay (A). 
Cultures were performed either with or without 20 ng/ml exogenously added VEGF. Cords were visualized by human CD31 
staining (green). Both early passage neonatal and adult NHDF cells are more supportive for cord formation than the late pas-
sage adult NHDFs, with the late passage NHDF cells being non-permissive. (B). Clustering analysis of genes involved in angio-
genesis. P6 NHDFs from a neonatal donor (Neo P6), P4 NHDFs from an adult donor (Ad P4), and P13 NHDFs (Ad P13) from 
the same adult donor were assayed for basal gene expression using the Affymetrix GeneChip platform. 787 nonredundant 
genes were identified as common differentially expressed genes between the two early passage NHDF and the late passage 
NHDF cells. Enrichment testing was used to identify significant Biological Process (BP) categories. Representative angiogenesis 
BP categories are shown in a heatmap visualization.BMC Genomics 2008, 9:264 http://www.biomedcentral.com/1471-2164/9/264
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and regulation (see Additional file 3). There were 1201
unique genes in the interactome, among which 887 genes
were differentially expressed in the co-culture system.
Thus, the interactome covers roughly 74% of the identi-
fied DEGs. The interactome displays the typical character-
istics of a scale-free network [22] (Fig. 4). Thirty genes
with the highest connectivity are listed in Table 3. We fur-
ther identified 823 angiogenesis-related genes by conduct-
ing automated querying of the PubMed abstract database
using an in-house developed text mining tool, Target-
Miner. The thirty most connected genes in the interac-
tome were all angiogenesis related, accounting for over
33% of the total 17226 connections in the interactome.
This data suggests a high degree of relevancy of the inter-
actome to angiogenesis.
Subnetwork analysis of oncogene involvement in 
angiogenesis
The information on which the network was based comes
from many cell types. Although we filtered and refined the
network by only including genes that are present in the
model, validating 17226 individual network edges is chal-
lenging. We explored the feasibility of using the present
network model to address known biological phenomena
as a pathway toward functional validation of the network.
Examining the connectivity hierarchy, we found that
oncogenes and tumor suppressor genes are among the
highest ranked molecules (hub nodes) based on the
number of connections in which they are directly
engaged. For example, the number of connections that
P53, SRC, and MYC directly engaged is 301, 243, and 173
respectively, ranking at the 2nd, 8th and 16th places in terms
of connectivity in the interactome. This observation reca-
pitulates the emerging role of oncogenes and tumor sup-
pressor genes in angiogenesis regulation [1,5,23,24]. We
focused our analysis on MYC by first dissecting its interac-
tions with other genes in the network. A subnetwork cen-
tered on MYC was constructed from the initial
interactome (Fig. 5A). It was found that MYC is linked to
a variety of angiogenesis regulators with high connectivity
within the network, suggesting a central role of MYC in
angiogenesis regulation. We hypothesized that inactiva-
tion of MYC function would have profound angiogenic
defects in this co-culture assay. We tested this hypothesis
by attenuating MYC expression in HUVECs using c-MYC
siRNA. Cord formation was significantly suppressed in
siMYC treated cultures (Fig. 5B &5C). Cord mass, branch-
ing pattern, and responsiveness to exogenous VEGF were
all inhibited, which is consistent with the network predic-
tion. Knockdown of MYC expression by the siRNA was
confirmed in parallel by TaqMan RT-PCR analysis (Fig.
5D). The involvement of TGF-β, the top node in the
present angiogenesis network was also validated (data not
shown).
Assessment of compound antiangiogenic activity by 
network perturbation analysis
We further explored the application of network analysis to
understand compound polypharmacology. Since kinases
have increasingly become effective targets for anti-ang-
iogenic drug discovery [25-27], we assessed kinase contri-
butions to angiogenesis regulation in the co-culture
model by network analysis. First, 39 kinases were mapped
to the interactome with a total of 525 directly-connected
Table 2: Gene Ontology terms enriched with differentially expressed genes in NHDF cells of different passages
GO1 GO Term DEG2 FDR3
Biological Process blood vessel development 64 0.00700
vasculature development 64 0.00700
actin filament organization 40 0.00850
actin cytoskeleton organization and biogenesis 81 0.00850
actin filament-based process 84 0.00850
regulation of signal transduction 98 0.01020
angiogenesis 56 0.01140
blood vessel morphogenesis 60 0.01140
cell morphogenesis 161 0.02020
Cellular Component extracellular matrix 75 0.00200
proteinaceous extracellular matrix 74 0.00200
actin cytoskeleton 60 0.04800
adherens junction 30 0.06140
cell-matrix junction 25 0.06140
cytoskeleton 132 0.06140
Molecular Function protein binding 864 0.00820
binding 1195 0.01740
cytoskeletal protein binding 95 0.02380
1. Gene Ontology; 2. Differentially expressed genes; 3. False discovery rate.
Listed are GO categories identified through enrichment testing of the differentially expressed genes from NHDF cells using the DAVID functional 
annotation system as described in the methods section.BMC Genomics 2008, 9:264 http://www.biomedcentral.com/1471-2164/9/264
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genes, accounting for 44% of the total number of genes in
the refined interactome. Any mapped kinase is engaged in
the rest of the network through multi-step connections.
Accordingly, we developed a "network walking" algo-
rithm to model the connection cascade of kinases within
the network. The methods are described in the method
section and shown in a schematic diagram in Fig. 6. Using
this algorithm, the characteristic connection curves of the
39 mapped kinases were determined and are shown in
Fig. 7A. All kinases were able to connect to the rest of the
interactome (except for singletons), and the connectivity
plateaus at the connection of 1040 within the interac-
tome. This property was used to assess the potential max-
imal perturbation of the interactome if a given kinase is
inhibited. While every connected molecule plateaus at the
same number of connections, each arrives at a different
rate, which can be assessed by the slope of the connectiv-
ity curve. Since the spread of activity along the network
can not reach 100 percent penetration at each step, and
the penetration is expected to decay dramatically at later
steps due to multiple inputs and outputs at each node, we
thus defined a perturbation index calculated from the data
collected by the network walking algorithm using a
weighted sum method as described in the method section.
Using network perturbation analysis to assess drug phe-
notypic activity, we tested three multi-targeted anti-ang-
iogenic kinase (MAK) inhibitors: Sunitinib, PTK787, and
LY2401401. The analysis was performed based on the
number and the identities of the kinases that are inhibited
by a given compound at its respective potency as
described in the method section. Sunitinib and PTK787
have been previously tested in clinical trials [25], while
LY2401401, is a novel Lilly MAK inhibitor with a distinct
kinase activity profile. LY2401401 (Fig. 7B), an imidazo-
pyridine, is an orally bioavailable, broad-spectrum inhib-
itor of the VEGF and PDGF receptors. Additionally, Flt3,
Kit, Tie-2 and the Eph family of receptors are also sensitive
to this small molecule inhibitor (SMI). To differentiate
these MAK compounds, it is important to determine if the
unique kinase profile of LY2401401 is advantageous to
achieve anti-angiogenic efficacy. We simulated the poten-
tial network perturbation by the three molecules based on
the integrated perturbation index of every kinase that a
given SMI is active against. The resulting theoretical dose
response curves were used to estimate the simulated EC50
of network perturbation (Fig. 7C). The compounds were
ranked by their simulated activities as
Table 3: The most connected thirty molecules in the 
interactome
Rank Gene Connectivity Percentage
1T G F B 1 3 9 7 2
2T P 5 3 3 0 1 4
3I G F 1 2 9 0 6
4 MAPK1 270 7
5F G F 2 2 6 1 9
6P D G F 2 5 1 1 0
7A K T 1 2 4 8 1 2
8S R C 2 4 3 1 3
9J U N 2 4 2 1 5
10 AGT 231 16
11 SP1 230 17
12 IL6 220 18
13 IL1B 216 20
14 NGFB 207 21
15 VEGF 183 22
16 MYC 173 23
17 MAPK8 169 24
18 HGF 168 25
19 RAF1 162 26
20 MAPK3 156 27
21 CREB1 146 28
22 EP300 141 28
23 EGFR 138 29
24 CDKN1A 122 30
25 RAC1 117 31
26 STAT3 115 31
27 BCL2 109 32
28 PRL 108 33
29 PPARG 103 33
30 NR3C1 101 34
Genes within the regulation network or interactome were ranked by 
their connectivity in the network, i.e., the number of genes that they 
directly engaged with. Listed above are the top 30 genes with the 
highest connectivity. Gene symbols are those assigned by Human 
Gene Nomenclature Committee (HGNC).
Interactome analysis of the gene functional association in the  HUVEC/NHDF co-culture Figure 4
Interactome analysis of the gene functional associa-
tion in the HUVEC/NHDF co-culture. The interactome 
that was built with PathwayAssist from a union of differen-
tially expressed genes identified in the microarray studies 
consists of 17226 connections among 1201 genes. The distri-
bution of the number of connections for 1201 genes is 
sorted by its connectivity, which acts as a typical scale-free 
network.BMC Genomics 2008, 9:264 http://www.biomedcentral.com/1471-2164/9/264
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LY2401401>Sunitinib>PTK787, with the EC50 values
estimated to be 7.8 nM, 13.6 nM, and 133.7 nM, respec-
tively. The network analysis clearly differentiates these
three MAK molecules. Interestingly, the network analysis
predicted that Sunitinib would be far more potent than
PTK-787, although their activities against KDR are rather
close (49 nM, and 58 nM, respectively for PTK-787 and
Sunitinib).
We then determined the actual angiogenesis activity of
each compound by testing its dose dependent response
directly in the cord formation assay. They were ranked in
the same order as inferred by the network simulation (Fig.
7D). The observed EC50 values from multiple independ-
ent experiments were determined to be 9.2 nM (± 9.1 nM
s.d.; n = 3), 39.0 nM (± 9.2 nM s.d.; n = 4), and 140.4 nM
(± 53.7 nM s.d.; n = 2) for LY2401401, Sunitinib, and
PTK787, respectively (Fig. 7D). The actual compound
activity in the cord formation bioassay was consistent
with the predicted values based on the network perturba-
tion analyses.
Analysis of the involvement of MYC oncogene in angiogenesis Figure 5
Analysis of the involvement of MYC oncogene in angiogenesis. (A). Subnetwork analysis of MYC in the interactome. 
Differentially expressed genes identified from the HUVEC and NHDF microarray studies were used to build a gene regulation 
interactome as described in the method section. Genes connected to MYC were extracted from the interactome and visual-
ized by building a MYC centric subnetwork. (B). Validation of the involvement of MYC in cord formation by siRNA mediated 
gene silencing. Expression of MYC in the HUVECs was attenuated by transfecting the cells with siRNA against MYC (siMYC). 
The siRNA treated HUVECs were co-cultured with regular NHDF cells. siRNA against luciferase (siLUC) was used as the neg-
ative control. Knocking down the MYC expression in HUVECs impaired cord formation either in the presence or absence of 
20 ng/ml VEGF. (C). Quantitation of cord area and angiogenesis index from the siRNA experiment. (D). Validation of reduced 
MYC expression in the siMYC treated HUVECs by TaqMan RT-PCR analysis. Data are expressed as Mean ± S.D.BMC Genomics 2008, 9:264 http://www.biomedcentral.com/1471-2164/9/264
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Discussion
Angiogenesis involves various cellular and multi-cellular
events such as cell proliferation, survival, differentiation,
migration, branching and sprouting. Such complicated
processes are integrated via intrinsic and extrinsic regula-
tory mechanisms. Studying angiogenesis in the context of
a global gene association network is critical to better
understand angiogenesis and to improve cancer drug tar-
geting strategies. For instance, through network analysis,
peroxisome proliferative-activated receptor δ was recently
identified as a "hub" node in a network that plays critical
roles in mediating a tumor angiogenesis switch in human
pancreatic cancers [28]. Over several decades, many
proangiogenic factors have been uncovered, subsets of
which are used by various malignant tumors preferen-
tially [1,8]. However, the proangiogenic signals used by
tumors are not static. It is thus unlikely to find a pleio-
tropic therapy by targeting a single proangiogenic factor.
Moreover, tumors develop escape strategies by expressing
alternative proangiogenic factors [13]. Unsurprisingly,
mixed results have been observed in clinical trials with
anti angiogenesis agents being used as a mono therapy or
in combination therapies [27,29,30]. It has been well
accepted in the field that targeting a single gene is not suf-
ficient [31]. However, how to target multiple genes? What
are the desirable combinations of targets? And how to
achieve efficacy with less rebound possibility? These are
some key issues to be addressed. In this light, a compre-
Schematic diagram of the network algorithm to estimate connectivity index (Ci) from the interactome Figure 6
Schematic diagram of the network algorithm to estimate connectivity index (Ci) from the interactome. Filled 
circles represent the ith gene (i = 1,2, ..., K), and filled diamonds the other genes reported in the literature to have one or more 
functional associations with the ith gene. Broken arrows are associations that were not taken into the calculation due to the 
reverse direction along the connection path. Li,j is the number of unique genes connecting to the ith gene at the jth step, Ci,j is the 
connectivity of the ithgene at the jth step, and Ci is the connectivity of the ith gene, which is the limit of Ci,j.BMC Genomics 2008, 9:264 http://www.biomedcentral.com/1471-2164/9/264
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hensive gene association network governing angiogenesis
is needed to aid rational anti-angiogenesis drug design.
In the present study, we first characterized an in vitro ang-
iogenesis co-culture model using high content imaging
analysis and found that cord formation is highly cell-pas-
sage dependent. We then profiled HUVEC and fibroblast
cells at different passages, from which we identified more
than two thousand genes whose expression was passage-
dependent. Using a natural language processing algo-
rithm, we retrieved a large collection of reported func-
tional associations (binding, regulation, transport and
modification) among identified genes. Analysis of the
interactome indicated that it is functionally related to ang-
Assessing compound phenotypic activity through network perturbation analysis Figure 7
Assessing compound phenotypic activity through network perturbation analysis. (A). Characteristic connection 
curves of 39 kinases mapped to the interactome. 39 kinases were mapped to the interactome; collectively, they directly con-
nect to 525 genes in the network. A network walking algorithm was developed to estimate the spread of the connectivity of 
each kinase by calculating the total number of nonredundant genes it connected at each step along the connection pathway. 
The smoothed connectivity curve of each of the 39 kinases was shown, with the maximum reaching 1040 for each kinase. Sum-
mation of connectivity for 39 kinases is represented by the broken line. (B). The chemical structure of LY2401401, a novel 
small molecule and a multi angiogenesis kinase inhibitor tested in the network perturbation experiment. (C). The connectivity 
index was calculated by an exponentially weighted sum of the connectivity at each stage of each kinase. The dose dependent 
network perturbation of each small molecule inhibitor was simulated as described in the methods section. The data were 
imported into Graphpad Prism software to estimate the EC50 values of network perturbation using Sigmoidal dose-response 
curve fitting. (D). Three small molecule kinase inhibitors were tested for cord formation. They all showed dose dependent 
inhibition of angiogenesis. Representative image summaries of the dose dependent responses are shown. The cord area data 
were imported to Graphpad Prism software, and normalized to the control group for EC50 calculation, using the same method 
as the one that was used to calculate the simulated network perturbation values. Shown in the figure are mean EC50s for each 
compound, averaged from two to four independent experiments.BMC Genomics 2008, 9:264 http://www.biomedcentral.com/1471-2164/9/264
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iogenesis. Topologically, it displayed a typical characteris-
tic of a scale-free network system, that is, 20% of genes
account for 80% of functional connections. The interac-
tome recapitulated the involvement of oncogenes in ang-
iogenesis regulation, which was subsequently validated
by siRNA mediated gene silencing. We further hypothe-
sized that the interactome we constructed is essential and
sufficient to support angiogenesis in the co-culture model
system.
Anti-angiogenic efficacy from a given drug can be thought
of as its ability to disrupt essential functional associations
in the interactome. Conceivably, inhibitors capable of
affecting more hub nodes should deliver faster and
stronger network perturbation, eliciting enhanced anti-
angiogenic efficacy. Therefore, we implemented a network
walking algorithm to calculate connectivity indices in the
interactome. The connectivity index for the ith gene is a
quantity extracted from the interactome that measures its
effectiveness in perturbing the entire angiogenesis interac-
tome on inhibition. This is important as a way to address
the important polypharmacology of anti-angiogenic com-
pounds.
The present study takes kinase inhibitors as an example.
Targeting multiple kinases is generally believed to be a
viable antiangiogenic strategy and has been proven clini-
cally [25-27,29]. Sunitinib and Nexavar (sorafenib), two
small molecule kinase inhibitors, are currently registered
therapies. However, PTK-787 failed to achieve statistical
significance in clinical trials [32], although the exact
mechanism accounting for the failure is not clear. Target-
ing the right spectrum of kinases by a single SMI is critical
for the development of successful anti-angiogenic drugs
[31]. Although many kinases are reportedly angiogenesis
related, they may differ in downstream signalling events,
crossreactivity, kinetics, etc. For a given small molecule
kinase inhibitor, translation of its kinase profile to pheno-
typic activity is challenging. In the present study, we
explored the feasibility of estimating the anti-angiogenic
activity of a kinase inhibitor via network perturbation
analysis. The current heuristic approach addressed the
number and identity of the kinases that a given com-
pound is active against as well as the respective potency.
The simulation was conducted to estimate network per-
turbation by a novel MAK compound LY2401401 along
with two clinically tested MAK compounds. The estimated
anti-angiogenic activities for the three kinase inhibitors
from the simulation were found to match well with their
actual activities on separate bioassays (Fig. 7). Because the
current network contains more than 17,000 edges, it
would be desirable if the network could be further refined
by more stringent filtering to potentially increase its pre-
dictive power. This might be done by refining the network
using network connections inferred directly through com-
prehensive microarray studies, or directly generated pro-
tein-protein interaction data. In addition, the complexity
of the current interactome, which contains data of differ-
ent types, makes systematic filtering in an unbiased way
difficult and should be considered for future studies.
Inferring a regulatory network from DNA microarray data
remains a great challenge despite the fact that numerous
computational methods have been published [33-39].
Biological processes are complex and involve hundreds of
genes, thus requiring a large amount of diverse data. In
addition, DNA microarray experiments only interrogate
transcriptionally-regulated genes, so it is inevitable that a
significant portion of false positive and false negative
interactions in an inferred network will be generated. In
the present study, instead of directly inferring a regulatory
network, we constructed an interactome from differen-
tially expressed genes by applying a literature text mining
technique to extract functional associations that had been
observed from experiments; thus we anticipate fewer false
positives. With the shortest path approach, we could
recover functional associations among genes where the
expression is not transcriptionally regulated, thus we
anticipate fewer false negatives. For example, 20% of the
genes constituting our interactome were not differentially
expressed either in the HUVEC or NHDF cells, yet they
ranked rather highly in the connectivity hierarchy. Since
the natural language processing of literature text can be
error-prone, the interactome we constructed has its own
limits. The current approach is limited to address the com-
plexity of in vivo cancer angiogenesis which not only
involves multiple cell type and signalling pathway interac-
tions, but the interactions are also geometrically and tem-
porally restricted. For example, anti-angiogenic drug-
induced inhibition of vessel formation subsequently
causes changes in blood flow and creates hypoxic regions
in the tumor. Such changes are highly heterogeneous and
can be further compounded by many other human fac-
tors. Although HIF is one of the key nodes identified in
our interactome, applying network analysis to address in
vivo angiogenesis is still challenging. Moreover, the cur-
rent interactome is a collection of functional associations
among participating genes without the inclusion of feed-
back regulatory mechanisms; it is not suitable for an
advanced dynamic or kinetic analysis. For these reasons,
we took advantage of a general statistical property of a
biological network, namely, the characteristics of a scale-
free network system [22]. The network walking algorithm
captures unevenly distributed connectivity among func-
tionally associated genes in the constructed angiogenesis
interactome and uses that information to calculate how
much and how fast an external perturbation of the net-
work can be induced by a kinase inhibitor. This was then
used to estimate potential potency of the inhibitor for its
anti-angiogenesis effect. A near perfect match betweenBMC Genomics 2008, 9:264 http://www.biomedcentral.com/1471-2164/9/264
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estimated and measured potencies proves the statistical
properties of the interactome are informative for network
perturbation analysis. It would be also very interesting to
extend our current network approach to other angiogen-
esis related data sets, such as the data generated from a
time course study, as well as applications beyond angio-
genesis in the future. In summary, our current effort
defined a comprehensive gene functional association net-
work and demonstrated the feasibility of assessing drug
phenotypic activity through network perturbation analy-
sis. Corroborative studies with a larger pool of com-
pounds, refined network parameters and an improved
modelling approach would be warranted in further inves-
tigations.
Conclusion
We characterized an in vitro angiogenesis co-culture
model via high content imaging analysis. We determined
that HUVEC competence and NHDF supportiveness of
cord formation are highly cell-passage dependent. We
built a comprehensive gene association network to model
angiogenesis regulation via complementary profiling of
passage dependent gene expression in two cell types that
constituted the co-culture model. We developed a novel
algorithm to extract connectivity information from the
gene functional association network. Using multi-targeted
anti-angiogenic kinase inhibitors as an example, our data
indicate the feasibility of applying network perturbation
analysis to assess drug polypharmacology and phenotypic
activities.
Methods
Reagents and Cells
Recombinant VEGF was purchased from R&D Systems
(Minneapolis, Minnesota). Human umbilical vein
endothelial cells (HUVECs) and Normal Human Dermal
Fibroblast (NHDF) cells and culture medium were pur-
chased from Cambrex (Walkersville, Maryland). Cells
were maintained in EGM with 10% FBS and FGM-2,
respectively for HUVECs and NHDFs, according to manu-
facture's instructions. In vitro angiogenesis co-culture
AngioKit and Optimized medium were purchased from
TCScellworks (Buckingham, UK).
In vitro angiogenesis assay
In vitro HUVEC cord formation co-culture was performed
using the AngioKit commercially available from TCScell-
works (Buckingham, UK) adapted to a 24-well format. To
test HUVEC and NHDF passage dependence effects, the
co-culture was done in house adapted to a 96-well format.
Briefly, HUVEC cells were co-cultured onto human der-
mal fibroblast feeder layers in Optimised medium (TCS-
cellworks, Buckingham, UK) for a total of about 12 days.
Treatment started the day when the plates were received;
usually three to four days after initial plating. Medium
with or without growth factors or compounds was replen-
ished every 2 to 3 days. Cells were fixed with 70% cold
ethanol at the end of the culture and processed for anti-
CD31/Alexa 488 immunofluorescence. To visualize
feeder layer fibroblasts, some cultures were stained using
a polyclonal antibody against Vimentin (Abcam, Cam-
bridge, Massachusetts) along with an Alexa 568 conju-
gated secondary antibody to examine the feeder cell
integrity. Nuclear staining was performed using Hoechst
staining (Invitrogen Molecular Probe, Carlsbad, Califor-
nia).
Immunofluorescence stained co-culture plates were
scanned using ArrayScan VTI (Cellomics, Pittsburgh,
Pennsylvania) and the multi-parameter tube formation
Bioapplication was used for quantification. Morphologi-
cal measurements included cord length, width, area, per-
cent connected cord, branching node and segment count,
nuclei per cord, angiogenic index (expressed as the per-
centage of area covered by connected tube), etc. General
cytotoxicity was monitored by examination of the nuclear
staining of the feed layers.
Attenuation of gene expression by siRNA
HUVECs were trypsinized by 0.05% Trypsin/EDTA (Invit-
rogen, Carlsbad, CA), and 1 × 106 cells were nucleofected
with siMYC (200 pmol each, Ambion, Austin, TX) using a
nucleofector device (Amaxa, Gaithersburg, MD) adopting
optimized A-034 protocols for HUVECs according to the
instructions from the manufacturer. Transfected cells were
appropriately diluted and plated in 96-well plates onto
the NHDF feeder cells for the initiation of the cord forma-
tion assay. Cells were also plated in parallel into 6-well
plates and collected in Trizol (Invitrogen, Carlsbad, CA)
48 h or 72 h later for total RNA extraction.
Real Time RT-PCR
Total RNAs were extracted from Trizol and cleaned by
RNeasy mini kit (Qiagen, Chatsworth, CA). Genomic
DNA contamination was removed by DNA-free kit
(Ambion, Austin, TX), and cDNA synthesis was done by
using a high capacity cDNA archive kit (Applied Biosys-
tems, Forster City, CA). The cDNAs were used as templates
for real-time PCR with a universal PCR master mix
(Applied Biosystems, Foster City, CA). Real time PCR was
performed on a ABI 7900 HT. The average values were
normalized to 18s rRNA. Delta CT method was applied to
calculate the relative gene expression level [40].
RNA isolation and microarray experiments
RNA isolation and microarray studies were performed as
described previously [41]. Briefly, HUVECs and NHDFs
with different passages were cultured to about 80% con-
fluency. RNA was isolated using Trizol™ (Life Technolo-
gies, Inc. Invitrogen, Carlsbad, California) according toBMC Genomics 2008, 9:264 http://www.biomedcentral.com/1471-2164/9/264
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manufacture's instructions, and followed by cleanup
using RNeasy spin columns (Qiagen, Valencia, Califor-
nia). RNA labelling was performed on the Onyx robotic
system from MWG-Biotech and Aviso using the standard
labelling protocol. Biotin labelled cRNA was fragmented
and hybridized to human whole genome U133 plus 2
GeneChip (Affymetrix, Santa Clara, California). Chip
processing, imagine capturing, and raw data analysis were
performed using the Affymetrix Microarray Suite MAS
with default parameters.
Statistical analysis to identify differentially expressed 
genes
Hybridized microarrays were analyzed by the Affymetrix
microarray analysis software microarray suite 5 (MAS 5).
The chip signals were normalized using the default
method in Affymetrix MAS5, but setting the target at 2%-
trimmed mean to 1500 instead of 500. HUVEC were ana-
lyzed with four passages. We designated the cell passages
5, 8, 12 and 22 as 1, 2, 3 and 4 respectively. For each
probeset, the signal data were fitted to a linear regression
model of time to identify consistent gene expression
changes over cell passage. Three batches of the NHDF cells
were analyzed, including early passage neonatal NHDF,
early passage adult NHDF, and late passage adult NHDF
cells. To reduce a possible batch to batch effect, the MAS 5
signals for each chip were re-normalized by Local Polyno-
mial Regression Fitting (loess) approach using one neona-
tal sample as the baseline on a log scale. The re-
normalized signal data were fitted to an ANOVA model to
identify differential gene expression changes between the
different fibroblast cells.
To control for a false positive rate of testing the expression
change of thousands of genes simultaneously, the false
discovery rate (fdrate, or FDR) was estimated using an
algorithm derived from Benjamini and Hochberg [42].
Probesets with a false discovery rate of 0.2 or smaller were
considered as significant and followed up for further anal-
ysis. We excluded probesets called "absent" in all chips in
a data set. These probesets usually have very low expres-
sion signals. In addition, we used expression fold change
between different treatment conditions to filter out genes
to make sure the gene expression changes are biologically
meaningful.
PCA analysis was performed in R using the principal com-
ponent analysis function with standardized data [43]. The
first three principal components with > 80% variations
were exported into Spotfire (Sommerville, MA) to aid in
creating sample scatter plots. Hierarchical clustering anal-
ysis of DE genes was done in Spotfire with Euclidean dis-
tance by the complete linkage method.
To identify biological processes that were significantly
changed with passages, the identified DE genes were ana-
lyzed using the DAVID functional annotation system
(National Institute of Allergy and Infectious Diseases,
NIH) [21]. Significantly changed biological processes
were determined by the enrichment test provided by the
DAVID system. To control for a false positive rate of test-
ing the expression change of thousands of genes simulta-
neously, the false discovery rate (fdrate, or FDR) was
estimated using an algorithm derived from Benjamini and
Hochberg [42].
Construct angiogenesis related interactome and calculate 
connectivity index
A tentative interactome was constructed using PathwayAs-
sist from the union of the differentially expressed genes
identified either from the HUVEC or the NHDF array
experiment. PathwayAssist was configured to retrieve five
different types of relationships defined in the software,
namely, binding, expression, molecular transport, protein
modification and regulation. The software introduced
non-differentially expressed genes into the interactome in
order to establish the shortest connection pathway
between any two differentially expressed genes in the ini-
tial input gene list. This is an informative function since it
could recover potentially non-transcriptional regulatory
relationships between two or more genes. We cleaned up
this initial interactome by removing genes that were not
detected by either array study. In addition, genes that
could not connect to any other genes were called orphans
and removed from the interactome. Thus, the final ver-
sion of the interactome we constructed can be described
as follows:
Let G be the set of K genes in the interactome I, and R be
one of the five relationships: binding, molecular trans-
port, protein modification, inhibition or up-regulation.
Thus, the interactome I we built can be formally described
as
I = {(gi, gi) ∈ R | g ∈ G; i, j = 1,2, ... K}( 1 )
We assumed R is transitive, that is, if gene A regulates gene
B, and gene B regulates gene C, it is assumed that gene A
regulates gene C. Except for binding among the five types
of relationships, molecular transport, protein modifica-
tion, up-regulation and inhibition are unidirectional.
We wrote a "network walking" algorithm (Figure 6) in a
recursive function with which we calculated the number
of unique genes, Lij, connecting to the ith gene at the jth
step along the connection path in the interactome. We
define connectivity of the ith gene at the jth step along the
connection pathway asBMC Genomics 2008, 9:264 http://www.biomedcentral.com/1471-2164/9/264
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Ci,j = Ci,j-1 + Lij/2j-1 (2)
Thus, for the ith gene in the interactome its connectivity at
the jth step in its connection pathway is the connectivity at
the (j-1)th step plus weighted number of unique genes at
the jth step. We assigned 1/2j-1 as an arbitrary weight to the
number of unique genes connecting to the ith gene at the
jth step, that is, the weight exponentially decreases with the
number of steps away from the ith gene. Obviously Ci,j is a
non-decreasing function. We further define connectivity
of the ith gene Ci as
where Ci is the plateau of connectivity of the ith gene and
Ni the number of steps Ci,j takes to arrive at its limit or the
plateau. Since every gene in the interactome is connected,
the total number of genes a gene connects to is the same,
that is, after Ni steps the connectivity of the ith gene will
arrive at its plateau. However, they differ in the number of
steps Ni or the rate of the arrival at the plateau. Some genes
may take more steps than the others to arrive at the plat-
ueas, depending upon what and how many genes it con-
nects, especially at early steps. Schematic elucidation of
the algorithm is shown in Fig. 6.
Simulation of network perturbation
Let S be a small molecule kinase inhibitor, and Ps, D be the
level of network perturbation by the small molecule at a
hypothetical dose D. Ps, D is estimated as
where K is the number of kinases in the interactome I that
can be inhibited by the small molecule S, IC50i,s is the
IC50 value of the small molecule S against the ith kinase.
Their relative IC50 values against various kinases were
measured at Upsate (UBI) or in house. To simulate the
dose response curve, we set the theoretical dose D from
0.1 nM to 2 μM. If a term in (4) is more than the maxi-
mum number of the connected genes, the term is then set
to the plateau. Summed network connectivity was used to
calculate the percent perturbation with the plateau to be
set at 100% network perturbation. The resulted simulated
dose dependent network perturbation was then imported
into the program GraphPad Prism to estimate EC50 of
network perturbation by the small molecule S  by per-
forming Sigmoidal dose-response curve fitting.
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